Wenham RM - Search Results

1

Human cancer cell line microRNAs associated with in vitro sensitivity to paclitaxel.

Chen N, Chon HS, Xiong Y, Marchion DC, Judson PL, Hakam A, Gonzalez-Bosquet J, Permuth-Wey J, Wenham RM, Apte SM, Cheng JQ, Sellers TA, Lancaster JM. Chen N, et al. Among authors: wenham rm. Oncol Rep. 2014 Jan;31(1):376-83. doi: 10.3892/or.2013.2847. Epub 2013 Nov 13. Oncol Rep. 2014. PMID: 24220856 Free PMC article.

2

Molecular aspects of ovarian cancer.

Wenham RM, Lancaster JM, Berchuck A. Wenham RM, et al. Best Pract Res Clin Obstet Gynaecol. 2002 Aug;16(4):483-97. doi: 10.1053/beog.2002.0298. Best Pract Res Clin Obstet Gynaecol. 2002. PMID: 12413930 Review.

3

No relationship between ovarian cancer risk and progesterone receptor gene polymorphism in a population-based, case-control study in North Carolina.

Lancaster JM, Wenham RM, Halabi S, Calingaert B, Marks JR, Moorman PG, Bentley RC, Berchuck A, Schildkraut JM. Lancaster JM, et al. Among authors: wenham rm. Cancer Epidemiol Biomarkers Prev. 2003 Mar;12(3):226-7. Cancer Epidemiol Biomarkers Prev. 2003. PMID: 12646513 No abstract available.

4

Matrix metalloproteinase-1 gene promoter polymorphism and risk of ovarian cancer.

Wenham RM, Calingaert B, Ali S, McClean K, Whitaker R, Bentley R, Lancaster JM, Schildkraut J, Marks J, Berchuck A. Wenham RM, et al. J Soc Gynecol Investig. 2003 Sep;10(6):381-7. doi: 10.1016/s1071-5576(03)00141-2. J Soc Gynecol Investig. 2003. PMID: 12969782

5

MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN.

Yang H, Kong W, He L, Zhao JJ, O'Donnell JD, Wang J, Wenham RM, Coppola D, Kruk PA, Nicosia SV, Cheng JQ. Yang H, et al. Among authors: wenham rm. Cancer Res. 2008 Jan 15;68(2):425-33. doi: 10.1158/0008-5472.CAN-07-2488. Cancer Res. 2008. PMID: 18199536

6

MicroRNAs and their target messenger RNAs associated with endometrial carcinogenesis.

Boren T, Xiong Y, Hakam A, Wenham R, Apte S, Wei Z, Kamath S, Chen DT, Dressman H, Lancaster JM. Boren T, et al. Gynecol Oncol. 2008 Aug;110(2):206-15. doi: 10.1016/j.ygyno.2008.03.023. Epub 2008 May 21. Gynecol Oncol. 2008. PMID: 18499237

7

MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy.

Boren T, Xiong Y, Hakam A, Wenham R, Apte S, Chan G, Kamath SG, Chen DT, Dressman H, Lancaster JM. Boren T, et al. Gynecol Oncol. 2009 May;113(2):249-55. doi: 10.1016/j.ygyno.2009.01.014. Epub 2009 Feb 23. Gynecol Oncol. 2009. PMID: 19237188

8

Evaluation of the porcine model to teach various ancillary procedures to gynecologic oncology fellows.

Hoffman MS, Ondrovic LE, Wenham RM, Apte SM, Shames ML, Zervos EE, Weinberg WS, Roberts WS. Hoffman MS, et al. Among authors: wenham rm. Am J Obstet Gynecol. 2009 Jul;201(1):116.e1-3. doi: 10.1016/j.ajog.2009.04.050. Am J Obstet Gynecol. 2009. PMID: 19576378

9

Electrothermal bipolar coagulation decreases the rate of red blood cell transfusions for pelvic exenterations.

Bansal N, Roberts WS, Apte SM, Lancaster JM, Wenham RM. Bansal N, et al. Among authors: wenham rm. J Surg Oncol. 2009 Nov 1;100(6):511-4. doi: 10.1002/jso.21372. J Surg Oncol. 2009. PMID: 19697350

10

Gedunin, a novel natural substance, inhibits ovarian cancer cell proliferation.

Kamath SG, Chen N, Xiong Y, Wenham R, Apte S, Humphrey M, Cragun J, Lancaster JM. Kamath SG, et al. Int J Gynecol Cancer. 2009 Dec;19(9):1564-9. doi: 10.1111/IGC.0b013e3181a83135. Int J Gynecol Cancer. 2009. PMID: 19955938

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

122 results

Search Page